Table 1 Baseline patient characteristics of 122 patients with CDI
Variable | Category | No. Of subjects n (%) |
|---|---|---|
Total number of subjects | Qatari residents | 122 |
Gender | Males | 72 (59%) |
Females | 50 (41%) | |
Age | 1-14 yrs | 23 (18.9%) |
15-30 yrs | 15 (12.3%) | |
31-50 yrs | 21 (17.2%) | |
51-64 yrs | 22 (18%) | |
≥ 65 yrs | 41 (33.6%) | |
Hospital acquired CDI | 98 (80.3%) | |
Community acquired CDI | 14 (11.5%) | |
Medical Records not available | 10 (8.2%) | |
Antibiotics used prior to CDI (some patients were on >1): | Tazocin | 55 (45.1%) |
Third generation Cephalosporins | 50 (41%) | |
Amoxicillin | 22 (18%) | |
Meropenom | 20 (16.4%) | |
Ciprofloxacin | 20 (16.4%) | |
Vancomycin | 15 (12.3%) | |
Co-trimoxazole | 10 (8.2%) | |
Azithromycin | 9 (9.8%) | |
Amikacin | 6 (7.4%) | |
Teicoplanin | 4 (3.3%) | |
Nitrofurantoin | 2 (1.6%) | |
Doxycyclin | 2 (1.6%) | |
Tigecyclin | 1 (0.8%) | |
Linezolid | 1 (0.8%) | |
Cloxacillin | 1 (0.8%) | |
Colistin | 1(0.8%) | |
Moxifloxacin, | 1 (0.8%) | |
Ampicillin | 1 (0.8%) | |
Septrin | 1 (0.8%) | |
Amygdalin | 1 (0.8%) |